ライフサイエンスコーパス: outcome

1 and legal and policy documents (intermediate outcome).

2 ine production relevant to asthma (secondary outcomes).

3 s, harms of treatment (twinning, respiratory outcomes).

4 at the different flow rates (P > .05 for all outcomes).

5 r preterm (<37 weeks) birth as a dichotomous outcome.

6 ed with improved cerebral edema and clinical outcome.

7 ll 377 infants were assessed for the primary outcome.

8 ure of the distal rectum and presumed better outcome.

9 litate a more predictable, optimal treatment outcome.

10 Cs) in the CNS, leading to improved clinical outcome.

11 l of black and white patients as a secondary outcome.

12 ee of hyperkalemia is in determining patient outcome.

13 s a risk factor for inferior renal allograft outcome.

14 6 months (defined as 1-LTFU) as the primary outcome.

15 ound the alkene strongly affect the reaction outcome.

16 eded to assess safety and long-term clinical outcome.

17 ous intensive care are essential for optimal outcome.

18 us to achieve a highly effective therapeutic outcome.

19 ng tumor metabolism could change therapeutic outcome.

20 these isoforms affect cancer progression and outcomes.

21 orter assays failed to reproduce the similar outcomes.

22 cident chronic kidney disease were secondary outcomes.

23 ors typically associated with poor treatment outcomes.

24 ral factors translating into poorer clinical outcomes.

25 isk marker for vulnerability and poor health outcomes.

26 a is common and is linked to adverse patient outcomes.

27 ns and is associated with deleterious health outcomes.

28 is safe and effective in improving clinical outcomes.

29 an infarct-related coronary artery improves outcomes.

30 tive maintenance therapy could improve their outcomes.

31 ochasticity varies greatly among demographic outcomes.

32 ity score-matched cohorts to investigate the outcomes.

33 la development and other major postoperative outcomes.

34 Plasmodium parasitemia had no impact on EVD outcomes.

35 elopmental factors to fertility preservation outcomes.

36 eterogeneity of confounder associations with outcomes.

37 mended to capture long-term degree of health outcomes.

38 ked the latent growth of cumulative economic outcomes.

39 al environment may influence transplantation outcomes.

40 experience has been shown to effect surgical outcomes.

41 lfide donors are likely to improve pregnancy outcomes.

42 ementary prognostic information on long-term outcomes.

43 consistently associated with worse clinical outcomes.

44 elp further optimize medications and improve outcomes.

45 direct effects of exposure on severe health outcomes.

46 ed its impacts on first-line ART virological outcomes.

47 ses' knowledge, quality of care, and patient outcomes.

48 y and reduced amygdala reactivity to salient outcomes.

49 ion of ART with longitudinal cervical lesion outcomes.

50 ll patients is associated with poor clinical outcomes.

51 increased risk of any of the other secondary outcomes.

52 tive value regarding tumor grade and patient outcomes.

53 AF was associated with increased risk of all outcomes.

54 h infection who are at elevated risk of poor outcomes.

55 n children with DCM and is useful to predict outcomes.

56 ns between arginine intake and adverse birth outcomes.

57 ociation of maternal PHIV status with infant outcomes.

58 e clinically reported difference in surgical outcomes.

59 ntial to predict ecological and evolutionary outcomes.

60 ions in terms of patient characteristics and outcomes.

61 needed on procedural and long-term clinical outcomes.

62 ensity, Medicare payments, and perioperative outcomes.

63 ioned inhibitors for two distinct appetitive outcomes.

64 , 0.79; 95% CI, 0.23-1.35) and the composite outcome (1680 [12.2%]) vs 1383 [10.1%]; % absolute RD, 2

65 We analyzed the outcome after MV repair (n=1709) and replacement (n=213)

66 ues for promoting regeneration, the clinical outcome after nerve damage is frequently poor.

67 EL and DHL are both associated with inferior outcomes after ASCT in patients with rel/ref DLBCL.

68 gher circulating soluble AXL had poor 1-year outcomes after ICH onset, suggesting that therapeuticall

69 ork of randomized clinical trials to compare outcomes after specific treatment durations.

70 B-cell lymphoma (DLBCL) associated with poor outcomes after standard chemoimmunotherapy.

71 of evidence for association with the primary outcome: age, vasopressor requirement, thrombocytopenia,

72 2013-14 influenza season attenuated adverse outcome among adults that were hospitalized with laborat

73 and survival probability with respect to NLP outcomes among eyes with congenital aniridia.

74 stronger associations between PM2.5 and both outcomes among lower- versus higher-income participants.

75 s at target and major adverse cardiovascular outcomes among patients with T1DM.

76 The relationship between postoperative outcome and preoperative pathology of white matter tract

77 nd time, which leads to compromised clinical outcome and promotes the spread of antibiotic resistance

78 otor control, a result supported by the dFNC outcome and the alcohol use disorder identification test

79 rude analysis of the association between the outcome and the presence of hyperplastic polyps in the b

80 ith PCR-confirmed influenza infection as the outcome and vaccination status defined by days between v

81 Risks of disease-related outcomes and 5-year recurrence-free, disease-specific, a

82 urpose of this study was to examine surgical outcomes and complication rates of dacryocystorhinostomy

83 Clinical outcomes and health care use through 6 months were obtai

84 c wound microbiome is indicative of clinical outcomes and may be a valuable guide for personalized ma

85 Here we report outcomes and risk factors for anal HSIL following implem

86 ffects models to assess associations between outcomes and the following categories of group attendanc

87 ated pooled OR for 3-month mortality (safety outcome) and 3-month death or dependency (modified Ranki

88 k on CrVI by external stakeholders (proximal outcome) and citations of NTP's research in scientific p

89 d by parent report and child report (primary outcome), and blood was collected from children to measu

90 Recruitment was powered for the primary outcome, and analysis was based on intention to treat.

91 for transplant within 1 year as the primary outcome, and disparity in the referral of black and whit

92 sponders with sexual orientation as a binary outcome, and International Classification of Diseases, T

93 uch as substance use, previous adverse birth outcomes, and demographic factors.

94 gery with rapid visual recovery, good visual outcomes, and minimal complications in most patients.

95 ited States and has improved access to care, outcomes, and patient satisfaction.

96 ication of infectious agents improve patient outcomes, antimicrobial stewardship, and length of hospi

97 Observed outcomes are consistent with slow rates of disease progr

98 Causative organisms and visual outcomes are similar to those reported in the prior deca

99 ions across providers so that differences in outcomes are truly attributable to differences in the ca

100 ly essential for both interpreting cognitive outcomes associated with CTE and for developing preventi

101 roup differences were seen for any secondary outcome at 4 weeks or the end of follow-up.

102 violent offending, respectively, as adverse outcomes at ages 15-35 years.

103 tudy provides evidence to support no overall outcome benefit from adjuvant anthracyclines in patients

104 We found no differences in clinical outcomes between MGUS patients and KT controls.

105 Herein, we compare the outcomes between the two groups.

106 rivation was negatively associated with some outcomes, but the effect was partly mitigated by the org

107 current study is to evaluate differences in outcome by applying five periodontitis case definitions

108 menting efferocytosis may improve functional outcomes by both reducing tissue injury and promoting th

109 n outcome measure should be used only if the outcome can be influenced substantially by providers (th

110 In contrast to expected hypothetical outcomes, collagen has limited conformational selectivit

111 while providing similar visual and anatomic outcomes compared with monthly dosing at 1 year.

112 Outcomes comprised infectious complications within 3 day

113 oth conditioned fear extinction and response-outcome conditioning, as expected based on prior studies

114 buckling of individual domains and thus the outcome configurations of planar-patterned hydrogels.

115 to ensure that short- and long-term clinical outcomes continue to improve.

116 147) in the following defined primary study outcomes: coping behavior with respect to itching (P < .

117 arers, and research assistants who collected outcome data were aware of group allocation; however, al

118 Outcomes did not differ among test and control groups.

119 We aimed at evaluating overall outcomes, direct and putative indirect effects of CMV, p

120 Outcomes (outcome domains) were then compared separately for each

121 as therapeutic adjuvants to improve disease outcomes during intracellular bacterial infections.

122 d aversion to uncertainty about the decision outcome (e.g., risk) or aversion to negative outcomes (e

123 outcome (e.g., risk) or aversion to negative outcomes (e.g., loss).

124 diate goal-directed learning by a process of outcome evaluation to gradually select appropriate motor

125 to tutor syllables, suggesting a process of outcome evaluation.

126 etention rates seldom exceeding 50% and poor outcomes following dropout, we must explore innovative s

127 The primary outcome for the phase 3 stage of the trial was overall s

128 0 and estimated PTBs and other adverse birth outcomes for infants borne by non-Hispanic black mothers

129 litating early detection and improved visual outcomes for patients with age-related macular degenerat

130 I and post-API investigations, diagnosis and outcomes for the first 100 patients who had API as part

131 years for all HIV-exposed infants; clinical outcomes for truly infected infants did not differ by st

132 st recent change in licensing, we review the outcomes from clinical trials in children with persisten

133 me is significantly associated with improved outcomes from MIPD, with a threshold of 22 cases per yea

134 infection and severe hypoxemia are expected outcomes from RBC transfusion that need to be weighted w

135 overexpression associated with poor clinical outcomes have been attributed to increased cell cycle pr

136 PA was related to the primary composite outcome (HF hospitalization, cardiovascular mortality, o

137 ed with poor short-term and long-term health outcomes; however, the frequency of AKI in children hosp

138 (5.54, 3.42), had no benefit on the primary outcome (HVLT-R-DR; difference in means -0.43 [95% CI -1

139 abnormalities are important risk factors for outcome in acute lymphoblastic leukemia.

140 sion of MYST3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast cancers.

141 tifies PR and CR as surrogates for long-term outcome in MGN.

142 for decision making and assessment of early outcome in patients eligible for transcatheter aortic va

143 ost-PCI FFR measurements to predict clinical outcome in patients from FAME 1 and 2 trials (Fractional

144 and healthy controls and assessed treatment outcome in patients.

145 rdiac complications may affect the long-term outcome in these patients and what modifiable factors ca

146 Visual and anatomic outcomes in a subgroup of laser control eyes receiving t

147 ial fibrosis is linked with adverse clinical outcomes in adults after tetralogy of Fallot repair (rTO

148 and chemokine profiles on neurodevelopmental outcomes in humans.

149 experience with DCDD from the Improving DCDD Outcomes in Liver Transplant consortium demonstrates sig

150 sor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMP

151 linical trial, called Resveratrol to Improve Outcomes in Older People With PAD (RESTORE), was conduct

152 ) is associated with less favorable clinical outcomes in patients with acute ischemic stroke caused b

153 f novel targeted agents has improved patient outcomes in several human cancers, no such advance has b

154 re is no generally accepted model to predict outcomes in stable coronary heart disease (CHD).

155 means of improving cognitive and depressive outcomes in well-designed studies incorporating comprehe

156 y (modified Rankin Scale (mRs) >/=3;efficacy outcome), in patients with acute ICH randomised to eithe

157 Secondary outcomes included a composite of mortality or other medi

158 Secondary outcomes included conversion to multiple sclerosis withi

159 Outcomes included cumulative CVD (coronary heart disease

160 Secondary outcomes included inflammatory markers.

161 Secondary outcomes included major adverse cardiovascular events.

162 Outcomes included symptoms, health status, and AF treatm

163 Study outcomes included the proportion of patients who were "d

164 injury is common and is associated with poor outcomes, including increased mortality, among criticall

165 calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and bleeding

166 ining momentum; however, its impact on major outcomes, including pancreatic fistula, has yet to be ad

167 re implicated in a variety of adverse health outcomes, including substance use disorders.

168 Key behavioral outcomes, including susceptibility, were replicated by t

169 During reward outcome, individuals with substance addiction showed inc

170 was necessary to pool primary and secondary outcomes.INT that is provided by a dietitian compared wi

171 We organised conceptually similar outcomes into 14 families to create summary indices.

172 For each prespecified outcome, IPD were analysed using a 1-stage approach.

173 tal cancer was associated with poor clinical outcome, irrespective of HIF-1 In addition, LOX was expr

174 etabolisms will integrate to reach a desired outcome is a difficult problem that has been studied in

175 t of ARDS and for important patient-centered outcomes like mortality.

176 ally by providers (that is, a strong process-outcome link exists) and statistical adjustment can be m

177 ver, Arf loss and p53 loss produce differing outcomes-loss of p53 promotes both tumor initiation and

178 Improvement of clinical outcome mainly relies on the declaration of adverse even

179 Secondary end points included clinical outcomes (major adverse cardiac events), use of healthca

180 An outcome measure should be used only if the outcome can b

181 xycholesterol levels in serum as the primary outcome measure.

182 baseline and every 4 weeks, with the primary outcome measured at 6 months.

183 A combination of multiple patient-reported outcomes measurement (PROM) tools is recommended to capt

184 Outcome measures defining the impact of globalization on

185 Main outcome measures include proportion of eye care provider

186 Secondary outcome measures included the time until onset of pain a

187 Outcome measures were incremental cost-effectiveness rat

188 The primary outcome measures were positive donor rim fungal culture

189 ysical and mental health, medication and BMI outcome measures.

190 Outcome Measures: HIV transmissions and deaths, years of

191 d that the inhibitor fasudil enhances action-outcome memory, resulting in goal-directed behavior in m

192 e of this marker as a predictor of long-term outcome merit further evaluation.

193 rmation that can be used to prognose patient outcome, monitor minimal residual disease, assess tumour

194 ithin the Eurotransplant Senior Program, but outcomes must be evaluated.

195 The primary outcome occurred in 325 patients (8.5%) in the degludec

196 , nested case-control study, we assessed the outcome of all (n = 95) renal transplanted patients with

197 f MMP-8 are associated with the risk for and outcome of cardiovascular diseases (CVDs).

198 tal efforts, which may in turn influence the outcome of cellular differentiation.

199 re was no significant change in the combined outcome of death or discharge to hospice (-1.3%/y [95% C

200 The outcome of interest was the age-adjusted incidence of HP

201 lular processing in hepatocytes and thus the outcome of liver-directed gene therapy using AAV vectors

202 it has heterogeneous effects on the clinical outcome of P. falciparum infection.

203 escribe the characteristics, management, and outcome of patients admitted to ICUs for pheochromocytom

204 p of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with

205 dequate dosing of antibiotics to improve the outcome of patients with sepsis.

206 ed with a more aggressive phenotype and poor outcome of patients, although more specific signatures h

207 rt to prematurity, because prematurity is an outcome of preeclampsia.

208 ial molecular target to improve the clinical outcome of severely burned patients.

209 tion, there was no difference in mean visual outcome of the first versus second NAION events (standar

210 clear how LAP shapes both the activation and outcome of the immune response at the molecular level.

211 natures related to the severity and ultimate outcome of the infection.

212 The primary outcome of the trial was the rate of corneal perforation

213 To compare usage patterns and outcomes of a nurse practitioner-staffed medical ICU and

214 iveness preferences, nor the fitness-related outcomes of attractiveness; (2) the neglected associatio

215 son's alpha-diversity index), with secondary outcomes of beta and gamma Simpson's and Shannon's diver

216 and vessels, which suggests that pathologic outcomes of centrosome overduplication depend on the tra

217 erious, avoidable, costly and common adverse outcomes of healthcare.

218 Our primary outcomes of interest were perinatal mortality, preterm b

219 Negative control outcomes of myocardial infarction (MI) and herpes zoster

220 We aimed to compare in-hospital outcomes of patients with CKD or ESRD with those patient

221 f this study was to obtain insights into the outcomes of people living with HIV who accessed services

222 h the SCC was differentially associated with outcomes of remission and treatment failure to CBT and a

223 Prospectively collected data and outcomes of SLT procedures performed between November 19

224 drive cells into apoptosis or senescence as outcomes of the DNA damage response (DDR).

225 The primary outcomes of the model were changes in life-years per 100

226 Guidelines-Stroke Registry, we examined the outcomes of use of thrombolytic therapy in patients with

227 Validation of simulated tissue outcomes on an independent set of human colorectal cance

228 Respiratory outcomes on discharge to home, at 1 year, and at age 18

229 Odds ratio (OR) for predicting poor outcome or standardized mean difference (SMD) of thyroid

230 Outcomes (outcome domains) were then compared separately

231 howed that oral voriconazole did not improve outcomes overall, although there may have been some effe

232 unctional outcome (P = 0.04), poor cognitive outcome (P = 0.03), post-stroke anxiety (P = 0.04) and p

233 ndependently associated with poor functional outcome (P = 0.04), poor cognitive outcome (P = 0.03), p

234 oter mutations alone did not predict adverse outcomes (P = 0.50), but the presence of TERT promoter m

235 METHODS AND In the OPEN CTO registry (Outcomes, Patient health status, and Efficiency iN Chron

236 t could be used as a biomarker of injury for outcome prediction or target for rehabilitation interven

237 of 34 Population, Intervention, Comparator, Outcome questions, five quality of evidence statements,

238 or the Population, Intervention, Comparison, Outcome questions.

239 s and Cox regression to determine the volume-outcome relationship, adjusting for demographic (sex, ag

240 What distinguishes fatal from non-fatal outcomes remains largely unknown, yet is key to optimisi

241 ants altered the learning rates used for the outcomes selectively, preferentially learning from the m

242 gh-volume centers had improved perioperative outcomes, short-term mortality, and overall survival.

243 eated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial.

244 ioning and contingency reversal to establish outcome-specific conditioned inhibitors for two distinct

245 raditional or improved stove use and primary outcomes, stratifying households by proximity to major i

246 e, the type of mechanical force controls the outcome: stretch induces cell division, whereas crowding

247 heterozygous patients in the majority of the outcomes studied.

248 risk of neurocognitive events in the ongoing outcome studies and post-marketing surveillance.

249 unction Questionnaire (IND-VFQ), and Medical Outcomes Study 36-item Short Form Survey (SF-36) were ob

250 sure might translate to sex-specific adverse outcomes such as behavioral deficits is a possibility th

251 insufficient to prevent some of the disease outcomes, such as development of bronchiectasis, anogeni

252 The Icatibant Outcome Survey (IOS) is an observational study monitorin

253 The Sino-Nasal Outcome Test score might be able to predict more severe

254 risk factors and are more predictive of poor outcomes than the rate of development of hyponatremia or

255 ce of childhood adversity on cardiometabolic outcomes that constitute the greatest public health burd

256 tivation of Smad3 has contrasting functional outcomes that may involve activation of an integrin/reac

257 explaining black-white differences in birth outcomes, the individual contribution of PM2.5 is compar

258 he beneficial effects of statins on clinical outcomes, the mechanisms underlying these effects remain

259 atrophy (p.Ser94Arg) and extend the clinical outcomes to a more severe spectrum with infantile lethal

260 tex (OFC) in rats to learning under expected outcome uncertainty in a novel delay-based task that inc

261 table fluctuations and directional shifts in outcome values.

262 n which EAP deficits lead to poor functional outcome via impaired cognition and increased negative sy

263 Primary outcome was 30-day mortality rate for all hospitalizatio

264 The primary outcome was a composite of long-term CV events or death,

265 The primary outcome was all-cause mortality until 28 days.

266 The primary outcome was all-cause mortality; myocardial infarction,

267 The prespecified outcome was alpha-diversity (inverse Simpson's alpha-div

268 The 3-month outcome was also comparable between the two ICH groups.

269 The main outcome was approval or rejection of PCSK9i prescription

270 The primary outcome was best-corrected visual acuity (BCVA) at 6 mon

271 Primary outcome was change from baseline in best-corrected visua

272 The primary outcome was change from baseline to 8 weeks in accelerom

273 Primary outcome was combined symptom medication score (CSMS) dur

274 cal usefulness of each score and the primary outcome was in-hospital mortality.

275 for the epileptiform versus non-epileptiform outcome was kappa = 0.40 (95% CI 0.25, 0.55).

276 The risk for any adverse birth outcome was lower among infants exposed from conception

277 The primary outcome was membership in high-symptom trajectories of 1

278 Primary outcome was mortality at 28-days.

279 Our secondary outcome was the diagnosis of overt PH in patients initia

280 The primary outcome was the incidence of adverse events among vaccin

281 The primary outcome was the number of laboratory-confirmed viral upp

282 dded value of the CMI in predicting survival outcomes was evaluated and compared with circulating tum

283 Information to predict bacterial therapy outcomes was provided by pretreatment tumor size and the

284 temperature, blood pressure, and heart rate outcomes were also significantly lower at 2 hours, but n

285 Outcomes were analyzed on the intention-to-treat-populat

286 Hazard ratios (HRs) for clinical outcomes were calculated for children with asthma in the

287 Procedural management and in-hospital outcomes were compared among patients treated at outlier

288 id social adjustment, diagnosis, and 20-year outcomes were examined.

289 Primary outcomes were rates of severe hypoglycemia and diabetic

290 Primary outcomes were repeat clinic presentations and growth ove

291 ted, only pharmacokinetic or pharmacodynamic outcomes were reported, or if ten or fewer patients were

292 The primary outcomes were the incremental cost-effectiveness values

293 Our primary outcomes were the projected number of additional unneces

294 Primary outcomes were time from presentation to documentation of

295 In the retrospective cohort, the primary outcomes were treatment failure and adverse events 14 da

296 nal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in ad

297 Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabil

298 associated with a higher odds of the primary outcome, whereas treatment in a facility with an observa

299 olled patients were assessed for the primary outcome, which was testing completeness within 30 days,

300 observational studies have indicated better outcome with intravascular ultrasound (IVUS) guidance wh